3rd major COVID-19 vaccine shown to be effective and cheaper

Virus Outbreak Vaccine Plan

FILE – In this July 30, 2020 photo, Kai Hu, a research associate transfers medium to cells, in the laboratory at Imperial College in London. Imperial College is working on the development of a COVID-19 vaccine. In a report to Congress and an accompanying “playbook” for states and localities, key federal health agencies and the Defense Department sketched out complex plans for a vaccination campaign to begin gradually early next year or later in 2020, eventually ramping up to reach any American who wants a shot. The Pentagon is involved with the distribution of vaccines, but civilian health workers will be the ones giving shots. (AP Photo/Kirsty Wigglesworth)

LONDON (AP) — Drugmaker AstraZeneca says that late-stage trials show its COVID-19 vaccine is highly effective, buoying the prospects of a relatively cheap, easy-to-store product that may become the vaccine of choice for the developing world.

The results announced Monday are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.

AstraZeneca is the third major drug company to report late-stage data for a potential COVID-19 vaccine. But unlike the others, the Oxford-AstraZeneca vaccine doesn’t have to be stored at freezer temperatures, making it potentially easier to distribute, especially in developing countries.

Categories: Coronavirus, National News